Back to News
Market Impact: 0.12
Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners
Source: PR Newswire
Company FundamentalsPatents & Intellectual PropertyM&A & RestructuringPrivate Markets & Venture
Haisco Pharmaceutical Group (002653) announced on Aug. 25 that it entered an exclusive licensing agreement with Sentivera, a new US venture backed by Population Health Partners and ARCH Venture. The news does not provide deal economics (e.g., upfront, milestone amounts, or royalties), limiting near-term clarity on financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
More News
- Why is T-Mobile stock tumbling today?
- This exchange stock is a buy on renewed options deal, Morgan Stanley says
- The AI race may be decided by financing—not just better chips
- Why is Verizon stock sliding today?
- OpenAI projected to bring in $20bn less in revenue than expected
- SpaceX wants to become a 'major mobile carrier' with low-band spectrum acquisition